Using Genomic-Based AI Technology to Advance Cancer Care

GE Healthcare and SOPHiA GENETICS have signed a letter of intent to collaborate on developing genomic-based artificial intelligence technology to advance cancer care. The goal of the technology is to better target and match a patient’s treatment based on her specific genomic profile and cancer type.

By using GE Healthcare’s extensive medical imaging capabilities and the SOPHiA DDM analytic genomic insight platform, the new artificial intelligence system will work to serve both the clinical and biopharma markets.

As cases of cancer continue to rise, there is an increasing demand for data-driven medicine. GE Healthcare will use its Edison platform to integrate data from several different resources, including the EHR, radiology information systems (RIS), imaging, and other medical device data.

By integrating data, it can be used to develop and deploy artificial intelligence solutions, simplifying the oncology patient workflow. Additionally, integrated data will help medical professionals better understand increasingly complex clinical patient data and compare the data between patients.

"The integration of genomics-based artificial intelligence into oncology workflow solutions would be a major breakthrough for integrated cancer medicine and for future clinical research, which increasingly depend on the ability to select those patients most likely to respond to new therapies," Jan Makela, President & CEO, Imaging at GE Healthcare said in a press release. "This collaboration represents another step in GE Healthcare's vision of making precision health—more efficient and personalized care—a reality."

GE Healthcare said it brings to the table a deep understanding of clinical workflows, learning AI algorithms for image reconstruction and segmentation, analytics, and standardization. Meanwhile, SOPHiA GENETICS is an institution in data-driven medicine.

SOPHiA GENETICS’ cloud-based analytic platform software uses AI and machine learning to develop actionable insights for clinicians and researchers from complicated datasets. Working together, these companies hope to break down the data silos across instruments and sites that often delay or prevent patients from receiving the best treatment for their condition.

"By bringing together our global platform and insights-sharing network with GE Healthcare's international reach and cutting-edge products, healthcare professionals will be able to leverage their expertise and work together for the benefit of patients all over the world. Cancer patients will be able to receive equal access to better diagnoses and treatments through secure data pooling and knowledge sharing, unlocking the promise of data-driven medicine at scale," Jurgi Camblong, co-founder and CEO, SOPHiA GENETICS said in a press release.

Next-generation sequencing (NGS) is quickly becoming the new standard of care for cancer diagnostics, especially as more therapies require genomic information to be prescribed in a personalized method. Today, these sets of information and insights are difficult for clinicians to easily and quickly obtain along the patient’s care journey. The shared goal of GE Healthcare and SOPHiA GENETICS is to simplify the process.